Ignite Creation Date:
2025-12-24 @ 1:12 PM
Ignite Modification Date:
2026-03-01 @ 9:54 PM
Study NCT ID:
NCT01397695
Status:
COMPLETED
Last Update Posted:
2019-09-06
First Post:
2011-07-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Sponsor:
University of California, San Diego
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
090666
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None